%0 Journal Article %A Gaëlle Munsch %A Louisa Goumidi %A Astrid van Hylckama Vlieg %A Manal Ibrahim-Kosta %A Maria Bruzelius %A Jean-François Deleuze %A Frits R. Rosendaal %A Hélène Jacqmin-Gadda %A Pierre-Emmanuel Morange %A David-Alexandre Trégouët %T Modelling of time-to-events in an ambispective study: illustration with the analysis of ABO blood groups on venous thrombosis recurrence %D 2021 %R 10.1101/2021.11.20.21266583 %J medRxiv %P 2021.11.20.21266583 %X In studies of time-to-events, it is common to collect information about events that occurred before the inclusion in a prospective cohort. In an ambispective design, when the risk factors studied are independent of time, including both pre- and post-inclusion events in the analyses increases the statistical power but may lead to a selection bias. To avoid such a bias, we propose a survival analysis weighted by the inverse of the survival probability at the time of data collection about the events.This method is applied to the study of the association of ABO blood groups with the risk of venous thromboembolism (VT) recurrence in the MARTHA and MEGA cohorts. The former relying on an ambispective design and the latter on a standard prospective one. In the combined sample totalling 2,752 patients including 993 recurrences, compared with the O1 group, A1 has an increased risk (Hazard Ratio (HR) of 1.18, p=4.2×10−3), homogeneously in MARTHA and in MEGA. The same trend (HR=1.19, p=0.06) was observed for the less frequent A2 group.In conclusion, this work clarified the association of ABO blood groups with the risk of VT recurrence. Besides, the methodology proposed here to analyse time-independent risk factors of events in an ambispective design has an immediate field of application in the context of genome wide association studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGM and D-AT are supported by the EPIDEMIOM-VT Senior Chair from the University of Bordeaux initiative of excellence IdEX. The MARTHA project was supported by a grant from the Program Hospitalier de la Recherche Clinique and the GENMED Laboratory of Excellence on Medical Genomics [ANR-10-LABX-0013], a research program managed by the National Research Agency (ANR) as part of the French Investment for the Future. The MEGA (Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis) study was supported by the Netherlands Heart Foundation (NHS98.113 and NHS208B086), the Dutch Cancer Foundation (RUL 99/1992), and the Netherlands Organization for Scientific Research (912-03-033|2003). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The MARTHA study was approved by the local Ethics Committee at La Timone Hospital (Marseille, France). The MEGA study was approved by the Medical Ethics Committee of the Leiden University Medical Center, the Netherlands.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. %U https://www.medrxiv.org/content/medrxiv/early/2021/11/21/2021.11.20.21266583.full.pdf